Published in Indian J Med Paediatr Oncol on October 01, 2010
Homeodomain-containing protein HOXB9 regulates expression of growth and angiogenic factors, facilitates tumor growth in vitro and is overexpressed in breast cancer tissue. FEBS J (2012) 0.98
Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem (2012) 0.98
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol (2013) 0.87
Hypoxia and metabolic adaptation of cancer cells. Oncogenesis (2016) 0.86
Grape seed extract and resveratrol prevent 4-nitroquinoline 1-oxide induced oral tumorigenesis in mice by modulating AMPK activation and associated biological responses. Mol Carcinog (2013) 0.82
The Fate of the Tumor in the Hands of Microenvironment: Role of TAMs and mTOR Pathway. Mediators Inflamm (2016) 0.82
Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem (2015) 0.81
AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest. PLoS One (2016) 0.80
Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol promotes angiogenesis in a mouse model. Cell Stress Chaperones (2015) 0.78
Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med (2013) 0.78
A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. Br J Cancer (2015) 0.78
(18)F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. Nucl Med Mol Imaging (2013) 0.76
Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res (2015) 0.75
Circular RNA alterations are involved in resistance to avian leukosis virus subgroup-J-induced tumor formation in chickens. Oncotarget (2017) 0.75
A Review of mTOR Pathway Inhibitors in Gynecologic Cancer. Oxid Med Cell Longev (2017) 0.75
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. Oncol Lett (2016) 0.75
PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes PTEN & LKB1 in human uterine leiomyomas. Indian J Med Res (2016) 0.75
TOR signaling in growth and metabolism. Cell (2006) 35.29
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem (2002) 4.19
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Glucose metabolism and cancer. Curr Opin Cell Biol (2006) 3.75
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol (2007) 2.47
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer (2002) 2.44
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J (2002) 2.25
Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology (2000) 2.16
mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res (2004) 2.14
Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet (2003) 2.09
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res (2006) 2.07
The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res (2007) 2.06
EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology (2008) 2.00
Biology of hepatocellular carcinoma. Ann Surg Oncol (2008) 1.78
Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res (2006) 1.72
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology (1998) 1.61
Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res (2001) 1.60
Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene (2006) 1.59
Therapeutic targets: MTOR and related pathways. Cancer Biol Ther (2006) 1.57
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer (2004) 1.56
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30
Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem (2002) 1.29
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs (2006) 1.25
HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer (2009) 1.17
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer (2006) 1.16
Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer (2006) 1.15
Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer (2008) 1.12
Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic beta-cells. Diabetes (2002) 1.07
Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol (2005) 1.05
Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci (2008) 0.99
Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol (2006) 0.97
Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med (2008) 0.93
Emerging drugs for the treatment of metastatic renal cancer. Expert Opin Emerg Drugs (2007) 0.80